Expert insights. Personalized for you.
About Psychedelic Science Funders Collaborative: Psychedelic Science Funders Collaborative (PSFC), a 501(c)(3) nonprofit, supports research on and clinical trials of physician-prescribed psychedelic medicines and patient … Read More. MORE
This epidemic affects not only patients, but their families and caregivers. Cannabis has given cancer patients relief , improved their mood and anxiety, and relieved insomnia. Mainstream media has begun to illustrate just how effective medical marijuana can be in helping cancer patients. National Public Radio (NPR) opened-up a dialogue about the needs of cancer patients to speak openly to their physicians about the benefits of medical marijuana. Patient Education MORE
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. It may also potentially address the underlying disease by enhancing skin integrity in a subset of EB Simplex patients. VANCOUVER, Nov. MORE
The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry. ” In observational models , patients with legal access to cannabis typically reduce or eliminate their use of opioids. In clinical models, CBD administration has been shown to reduce cravings for tobacco. MORE
The trials, to be tightly controlled in a hospital environment, are exempted from Japan’s Cannabis Control Act, which bans cannabis compounds generally. Ministry of Health, Labor and Welfare officials recently announced the trials during a meeting of the Okinawa-Northern Task Force, a research and development agency. In Japan, there are approximately 3,000 patients who suffer from Dravet Syndrome, and some 4,300 afflicted with Lennox-Gastaut. MORE
This is how Kristin Wilcox describes the effect a cannabis-infused drug given to her daughter, Shelby Mathews, during a clinical trial on cannabinoids for Dravet Syndrome. Patient Stories dravet syndrome epilepsy hydrocephalus Lenox-Gastaut syndrome patient rights Patient stories“I saw a change almost immediately. I can’t even explain … I can’t even describe it, but it was … It was like a light started coming back into her eyes.” MORE
Clinical trial results indicate cannabis could provide an alternative or adjunctive treatment to sickle cell patients. Marijuana Shows Promise In Sickle Cell Disease Treatment. MORE
The study found that medical cannabis use is associated with less frequent hospitalizations among patients living with sickle cell disease (SCD). It’s titled Medical marijuana certification for patients with sickle cell disease: A report of a single center experience. MORE
Here in Sydney we’d love to know the clinics and doctors that are actually prescribing. Hemp Gazette reports. …There’s a lot of activity on the Australian cannabusiness scene, but what is happening at the patient end of things? The important point to note with the figures above is they represent prescription approvals – not patients. A single patient may have had multiple approvals over the course of 2019. MORE
Clinical trials evaluating the use of human monoclonal antibodies against interleukin 1 and interleukin 6 to treat cytokine storm syndrome in COVID-19 patients are underway or in the planning stage. MORE
Depression can be situational, but Clinical Depression, which comes and goes and/or lasts for more than a few days, is a chemical imbalance within the central nervous system. Some patients find success with pharmaceuticals and talk-therapy. In addition to these medical interventions, Medical marijuana may also be beneficial to clinically depressed patients. Medical marijuana is another option for patients suffering from anxiety. MORE
There have been more than 7,500 approvals for medicinal cannabis in Australia since legalisation in 2016 – so why don’t we know if it is helping patients? Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government. Prescription occurs mostly on a case-by-case basis involving evidence that patients have failed to benefit from available conventional prescription medications. MORE
A medical marijuana patient in Los Angeles with inoperable liver cancer has been removed from Cedars-Sinai Medical Center’s transplant list after testing positive for marijuana. Sixty-three-year-old medical marijuana patient Norman B. “Denying necessary transplants to medical marijuana patients is the worse kind of discrimination,” said ASA Chief Counsel Joe Elford, who wrote the letter to Cedars-Sinai. MORE
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. It may also potentially address the underlying disease by enhancing skin integrity in a subset of EB Simplex patients. VANCOUVER, Nov. MORE
About Psychedelic Science Funders Collaborative: Psychedelic Science Funders Collaborative (PSFC), a 501(c)(3) nonprofit, supports research on and clinical trials of physician-prescribed psychedelic medicines and patient … Read More. MORE
This study’s primary outcome supports the theory that cannabis should be [tested in clinical trials] as a potential therapeutic for PTSD.". The post Study: Long-Term Cannabis Use Associated with Reduced Symptoms in Patients with Post-Traumatic Stress appeared first on NORML. MORE
"We conclude that phytocannabinoids can be a low-cost and well-tolerated therapy for symptom relief and quality of life improvement in these patients.". The post Clinical Trial: Plant-Derived Cannabis Oil Effective for Patients with Fibromyalgia appeared first on NORML. MORE
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. A team of Israeli researchers conducted a randomized placebo-controlled clinical trial to assess the safety and efficacy of a novel, metered-dose cannabis inhaler in 27 patients with chronic pain. MORE
According to a new study published in the journal Pain Medicine and epublished by the National Institute of Health, the daily use of marijuana oil is effective and well-tolerated among patients with fibromyalgia. On average patients received 3.6 MORE
An Introductory Lesson on THC Basics For Medical Cannabis Patients. Cannabis, a plant that has proven to be endlessly complex is still under the microscope by researchers, patients, physicians, and society. But many new patients need an introduction on THC basics, learning how it plays a role in a patient’s well-being and healing. The post THC Basics: An Introduction For Patients appeared first on Canna Care Docs. MORE
Metered-dose THC inhalers delivered consistent pain relief with minimal adverse effects for neuropathic patients, researchers found. Cannabis Medical Marijuana News RX cannabis inhalers chronic pain clinical trials Neuropathy THCAre Marijuana Inhalers Most Effective Treatment For Chronic Pain? The post Are Marijuana Inhalers Most Effective Treatment For Chronic Pain? appeared first on The Fresh Toast. MORE
The use of cannabidiol (CBD) is associated with both decreased anxiety and tremor amplitude in patients with Parkinson’s disease (PD), according to a new study published in the Journal of Psychopharmacology and first reported on by NORML. The study is titled Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson’s disease. MORE
This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. UK cannabis policy is not serving the interests of patients. MORE
VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV). MORE
The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine. Polish investigators conducted a randomized, double-blind placebo-controlled trial assessing the efficacy of twice-daily transdermal CBD administration on 60 patients with TMD over a period of 14 days. MORE
Fibromyalgia patients suffering from lower back pain respond favorably to medical cannabis as a treatment, according to a new study published in the journal Clinical and Experimental Rheumatology , and epublished by the National Institute of Health. For the study, researchers assessed the analgesic efficacy of both opioids and medical cannabis in 31 fibromyalgia (FM) patients with lower back pain. MORE
Dementia cannot be confirmed until a patient is deceased. Dementia is hard on the patient, and often harder on the family or caregivers. The clinical trials for medications take years and to this date, there have been no effective medications to properly treat and/or cure Dementia. Times article examined the effectiveness of Alzheimer’s disease medications for Dementia patients earlier in the course of the disease. cannabis education Patient Education MORE
” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5 ” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy. MORE
VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV). MORE
Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. In San Francisco and New York City, the physician-led pediatric studies will assess the viability of a purified cannabidiol as an anti-seizure treatment among patients with various forms of epilepsy. Although both studies will enroll 25 patients initially, the U.S. MORE
Most commonly, patients report that tingling and numbness occur, usually in the hands and feet. Additionally, the ACPA reported on a clinical trial that suggests that inhaled cannabis may provide short-term relief from Neuropathy. Six trials that included 325 patients examined chronic pain, 6 trials that included 396 patients investigated neuropathic pain, and 12 trials that included 1600 patients focused on multiple sclerosis. MORE
Living with PTSD, no matter the underlying cause of the trauma, can be extremely difficult for patients and their loved ones. According to a 2017 report published by the National Academies of Sciences , PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. Medical marijuana and cannabinoids can be used to treat a patient’s physical and psychological health, alleviating the symptoms of PTSD. MORE
There are a variety of treatment options to help patients cope with and heal from anxiety disorders. Medical marijuana is another option for patients suffering from anxiety. The research Men’s Journal is referring to is the 2017 journal article published in Clinical Psychology Review titled: Medical cannabis and mental health : A guided systematic review. The authors determined that patients are increasingly seeking Cannabis to treat a broad range of medical conditions. MORE
Because there is limited or conflicting research about “the true nature of traumatic brain injury and how it causes chronic degenerative problems,” treatment can be a challenging process for many patients. One medication may work for one patient, but might be ineffective for another TBI patient. The Brain Injury Association of America (BIAA) recognizes that no two brain injuries and its symptoms, are alike, and that also means that treatments will vary by patient. MORE
In January of 2020, the Journal of the American College of Cardiology published a review titled Marijuana Use in Patients With Cardiovascular Disease. Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease. MORE
Excluding potential drug:drug interactions, what adverse effects of CBD have been noted in clinical trials? In clinical trials evaluating CBD, adverse effects, including diarrhea, somnolence, decreased appetite, change in weight, and increased levels of liver enzymes have been noted. Of note, the one FDA-approved CBD product is associated with a higher risk of hepatotoxicity necessitating recommended scheduled liver function testing in patients starting the medication. MORE
Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care. Investigators affiliated with the Saint Anthony Hospital and Medical Campus in Colorado assessed the impact of the off-label use of dronabinol (FDA-approved synthetic oral THC) on opioid consumption patterns in trauma patients with acute pain. MORE
A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. The act ends the University of Mississippi’s existing monopoly on the growth of cannabis for clinical research purposes, by requiring the licensing of additional manufacturers. MORE
NORML
OCTOBER 30, 2020
"We conclude that phytocannabinoids can be a low-cost and well-tolerated therapy for symptom relief and quality of life improvement in these patients.". The post Clinical Trial: Plant-Derived Cannabis Oil Effective for Patients with Fibromyalgia appeared first on NORML.
NORML
FEBRUARY 25, 2020
Trauma patients administered oral THC consume fewer opioids than do similarly matched controls, according to clinical trial data published in the journal Trauma Surgery & Acute Care. Investigators affiliated with the Saint Anthony Hospital and Medical Campus in Colorado assessed the impact of the off-label use of dronabinol (FDA-approved synthetic oral THC) on opioid consumption patterns in trauma patients with acute pain.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
NORML
MAY 21, 2019
The administration of oral CBD reduces cue-induced cravings and anxiety in subjects with a history of heroin use, according to clinical data published in The American Journal of Psychiatry. ” In observational models , patients with legal access to cannabis typically reduce or eliminate their use of opioids. In clinical models, CBD administration has been shown to reduce cravings for tobacco.
NORML
MAY 26, 2020
The delivery of precise doses of THC via an inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions, according to clinical trial data published in the European Journal of Pain. A team of Israeli researchers conducted a randomized placebo-controlled clinical trial to assess the safety and efficacy of a novel, metered-dose cannabis inhaler in 27 patients with chronic pain.
NORML
DECEMBER 6, 2019
The transdermal application of plant-derived CBD reduces fascial pain in patients with temporomandibular disorders (TMD aka TMJ), according to clinical data published in the Journal of Clinical Medicine. Polish investigators conducted a randomized, double-blind placebo-controlled trial assessing the efficacy of twice-daily transdermal CBD administration on 60 patients with TMD over a period of 14 days.
Cannabis Law Report
MARCH 30, 2019
The trials, to be tightly controlled in a hospital environment, are exempted from Japan’s Cannabis Control Act, which bans cannabis compounds generally. Ministry of Health, Labor and Welfare officials recently announced the trials during a meeting of the Okinawa-Northern Task Force, a research and development agency. In Japan, there are approximately 3,000 patients who suffer from Dravet Syndrome, and some 4,300 afflicted with Lennox-Gastaut.
Puff Puff Post
MARCH 10, 2020
VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).
Puff Puff Post
NOVEMBER 5, 2019
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. It may also potentially address the underlying disease by enhancing skin integrity in a subset of EB Simplex patients. VANCOUVER, Nov.
NORML
DECEMBER 18, 2020
This study’s primary outcome supports the theory that cannabis should be [tested in clinical trials] as a potential therapeutic for PTSD.". The post Study: Long-Term Cannabis Use Associated with Reduced Symptoms in Patients with Post-Traumatic Stress appeared first on NORML.
Otherside Farms
JANUARY 24, 2019
Federal regulators have approved two clinical studies testing whether a marijuana-based epilepsy drug may help prevent seizures among epileptic children. In San Francisco and New York City, the physician-led pediatric studies will assess the viability of a purified cannabidiol as an anti-seizure treatment among patients with various forms of epilepsy. Although both studies will enroll 25 patients initially, the U.S.
Puff Puff Post
MARCH 10, 2020
VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).
The Fresh Toast
MAY 28, 2020
Metered-dose THC inhalers delivered consistent pain relief with minimal adverse effects for neuropathic patients, researchers found. Cannabis Medical Marijuana News RX cannabis inhalers chronic pain clinical trials Neuropathy THCAre Marijuana Inhalers Most Effective Treatment For Chronic Pain? The post Are Marijuana Inhalers Most Effective Treatment For Chronic Pain? appeared first on The Fresh Toast.
Puff Puff Post
NOVEMBER 5, 2019
5, 2019 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX: IN; OTCQX: IMLFF), today announced the filing of a Clinical Trial Application (“CTA”) in the Netherlands to initiate a Phase 1 human clinical trial for INM-755 in healthy volunteers. It may also potentially address the underlying disease by enhancing skin integrity in a subset of EB Simplex patients. VANCOUVER, Nov.
CannaTech
SEPTEMBER 23, 2019
This commentary on the NICE UK cannabis guidelines is originally published by The Academy of Medical Cannabis , the globally leading institute for clinical training and research in cannabis-based medicinal products. The acceptance of medical cannabis by clinicians, researchers and government bodies is fairly universal, and patients have benefited from widespread access to full-spectrum cannabis in flower and oil form. UK cannabis policy is not serving the interests of patients.
Otherside Farms
JANUARY 25, 2019
A medical marijuana patient in Los Angeles with inoperable liver cancer has been removed from Cedars-Sinai Medical Center’s transplant list after testing positive for marijuana. Sixty-three-year-old medical marijuana patient Norman B. “Denying necessary transplants to medical marijuana patients is the worse kind of discrimination,” said ASA Chief Counsel Joe Elford, who wrote the letter to Cedars-Sinai.
Leafwell
OCTOBER 17, 2018
This is how Kristin Wilcox describes the effect a cannabis-infused drug given to her daughter, Shelby Mathews, during a clinical trial on cannabinoids for Dravet Syndrome. Patient Stories dravet syndrome epilepsy hydrocephalus Lenox-Gastaut syndrome patient rights Patient stories“I saw a change almost immediately. I can’t even explain … I can’t even describe it, but it was … It was like a light started coming back into her eyes.”
Cannabis Law Report
DECEMBER 1, 2020
About Psychedelic Science Funders Collaborative: Psychedelic Science Funders Collaborative (PSFC), a 501(c)(3) nonprofit, supports research on and clinical trials of physician-prescribed psychedelic medicines and patient … Read More.
Cannabis Law Report
NOVEMBER 2, 2020
About Psychedelic Science Funders Collaborative: Psychedelic Science Funders Collaborative (PSFC), a 501(c)(3) nonprofit, supports research on and clinical trials of physician-prescribed psychedelic medicines and patient … Read More.
Canna Care Docs
JUNE 22, 2018
An Introductory Lesson on THC Basics For Medical Cannabis Patients. Cannabis, a plant that has proven to be endlessly complex is still under the microscope by researchers, patients, physicians, and society. But many new patients need an introduction on THC basics, learning how it plays a role in a patient’s well-being and healing. The post THC Basics: An Introduction For Patients appeared first on Canna Care Docs.
The Fresh Toast
JULY 22, 2020
Clinical trial results indicate cannabis could provide an alternative or adjunctive treatment to sickle cell patients. Marijuana Shows Promise In Sickle Cell Disease Treatment.
CannaMD
MARCH 8, 2020
In January of 2020, the Journal of the American College of Cardiology published a review titled Marijuana Use in Patients With Cardiovascular Disease. Few randomized clinical trials have been conducted or are planned to explore the effects of marijuana on cardiovascular risk. Screening and testing for use of marijuana are encouraged in clinical settings, especially in the care of young patients presenting with cardiovascular disease.
FloridaMarijuana.net
AUGUST 16, 2018
Dementia cannot be confirmed until a patient is deceased. Dementia is hard on the patient, and often harder on the family or caregivers. The clinical trials for medications take years and to this date, there have been no effective medications to properly treat and/or cure Dementia. Times article examined the effectiveness of Alzheimer’s disease medications for Dementia patients earlier in the course of the disease. cannabis education Patient Education
FloridaMarijuana.net
JUNE 13, 2018
This epidemic affects not only patients, but their families and caregivers. Cannabis has given cancer patients relief , improved their mood and anxiety, and relieved insomnia. Mainstream media has begun to illustrate just how effective medical marijuana can be in helping cancer patients. National Public Radio (NPR) opened-up a dialogue about the needs of cancer patients to speak openly to their physicians about the benefits of medical marijuana. Patient Education
The Joint Blog
AUGUST 27, 2020
The study found that medical cannabis use is associated with less frequent hospitalizations among patients living with sickle cell disease (SCD). It’s titled Medical marijuana certification for patients with sickle cell disease: A report of a single center experience.
TheAnswerPage
OCTOBER 11, 2020
Clinical trials evaluating the use of human monoclonal antibodies against interleukin 1 and interleukin 6 to treat cytokine storm syndrome in COVID-19 patients are underway or in the planning stage.
Cannabis Law Report
JANUARY 21, 2020
Here in Sydney we’d love to know the clinics and doctors that are actually prescribing. Hemp Gazette reports. …There’s a lot of activity on the Australian cannabusiness scene, but what is happening at the patient end of things? The important point to note with the figures above is they represent prescription approvals – not patients. A single patient may have had multiple approvals over the course of 2019.
TheAnswerPage
NOVEMBER 29, 2019
Excluding potential drug:drug interactions, what adverse effects of CBD have been noted in clinical trials? In clinical trials evaluating CBD, adverse effects, including diarrhea, somnolence, decreased appetite, change in weight, and increased levels of liver enzymes have been noted. Of note, the one FDA-approved CBD product is associated with a higher risk of hepatotoxicity necessitating recommended scheduled liver function testing in patients starting the medication.
The Joint Blog
NOVEMBER 24, 2018
Fibromyalgia patients suffering from lower back pain respond favorably to medical cannabis as a treatment, according to a new study published in the journal Clinical and Experimental Rheumatology , and epublished by the National Institute of Health. For the study, researchers assessed the analgesic efficacy of both opioids and medical cannabis in 31 fibromyalgia (FM) patients with lower back pain.
FloridaMarijuana.net
OCTOBER 19, 2018
Depression can be situational, but Clinical Depression, which comes and goes and/or lasts for more than a few days, is a chemical imbalance within the central nervous system. Some patients find success with pharmaceuticals and talk-therapy. In addition to these medical interventions, Medical marijuana may also be beneficial to clinically depressed patients. Medical marijuana is another option for patients suffering from anxiety.
Cannabis Law Report
AUGUST 19, 2019
There have been more than 7,500 approvals for medicinal cannabis in Australia since legalisation in 2016 – so why don’t we know if it is helping patients? Access to medicinal cannabis for patients was legalised in Australia in 2016, allowing doctors to request permission to prescribe from the Australian government. Prescription occurs mostly on a case-by-case basis involving evidence that patients have failed to benefit from available conventional prescription medications.
FloridaMarijuana.net
AUGUST 9, 2018
Because there is limited or conflicting research about “the true nature of traumatic brain injury and how it causes chronic degenerative problems,” treatment can be a challenging process for many patients. One medication may work for one patient, but might be ineffective for another TBI patient. The Brain Injury Association of America (BIAA) recognizes that no two brain injuries and its symptoms, are alike, and that also means that treatments will vary by patient.
The Joint Blog
JANUARY 18, 2020
The use of cannabidiol (CBD) is associated with both decreased anxiety and tremor amplitude in patients with Parkinson’s disease (PD), according to a new study published in the Journal of Psychopharmacology and first reported on by NORML. The study is titled Effects of acute cannabidiol administration on anxiety and tremors induced by a simulated public speaking test in patients with Parkinson’s disease.
NORML
APRIL 30, 2020
” The CDC’s interest in alternative methods of chronic pain management may be of particular significance to many medical cannabis patients. According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5 ” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy.
FloridaMarijuana.net
AUGUST 15, 2018
Most commonly, patients report that tingling and numbness occur, usually in the hands and feet. Additionally, the ACPA reported on a clinical trial that suggests that inhaled cannabis may provide short-term relief from Neuropathy. Six trials that included 325 patients examined chronic pain, 6 trials that included 396 patients investigated neuropathic pain, and 12 trials that included 1600 patients focused on multiple sclerosis.
NORML
JANUARY 17, 2019
A bipartisan coalition of House lawmakers has introduced The Medical Cannabis Research Act of 2019 ( HR 601 ), to facilitate federally-approved clinical trials involving cannabis. The act ends the University of Mississippi’s existing monopoly on the growth of cannabis for clinical research purposes, by requiring the licensing of additional manufacturers.
FloridaMarijuana.net
AUGUST 15, 2018
Living with PTSD, no matter the underlying cause of the trauma, can be extremely difficult for patients and their loved ones. According to a 2017 report published by the National Academies of Sciences , PTSD is a stressor-related disorder which develops as a result of a patient’s exposure to a traumatic event. Medical marijuana and cannabinoids can be used to treat a patient’s physical and psychological health, alleviating the symptoms of PTSD.
FloridaMarijuana.net
AUGUST 13, 2018
There are a variety of treatment options to help patients cope with and heal from anxiety disorders. Medical marijuana is another option for patients suffering from anxiety. The research Men’s Journal is referring to is the 2017 journal article published in Clinical Psychology Review titled: Medical cannabis and mental health : A guided systematic review. The authors determined that patients are increasingly seeking Cannabis to treat a broad range of medical conditions.
56 
Let's personalize your content